Fig. 7: Treatment with CDX0239-PBD leads to survival in ALK-expressing xenograft models. | Nature Communications

Fig. 7: Treatment with CDX0239-PBD leads to survival in ALK-expressing xenograft models.

From: A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Fig. 7

A Overall survival of neuroblastoma xenograft models NB-1, NB-SD, COG-N-424x, SK-N-AS, and NGP ALK wild-type (WT) with 3 weekly treatments of 1 mg/kg CDX0239-PBD (blue line) compared to IgG (gray line) and normal saline vehicle (black line). B Overall survival of colorectal carcinoma xenograft models HCT-116 and SW-48 and fusion-positive rhabdomyosarcoma xenograft model RH-41 with 3 weekly treatments of 1 mg/kg CDX0239-PBD (blue line) compared to IgG (gray line) and normal saline vehicle (black line). C Overall survival of neuroblastoma xenograft model NB-1 with a single 1 mg/kg dose of CDX0239-PBD (blue line) compared to normal saline vehicle (black line). D Overall survival of neuroblastoma xenograft model NGP ALK knockout (KO) with 3 weekly treatments of 1 mg/kg CDX0239-PBD (blue line) compared to IgG (gray line) and normal saline vehicle (black line). Each treatment condition includes a sample size of n = 5 mice and each experiment was completed once. All p-values represent CDX0923-PBD vs vehicle tumor volumes using Kaplan-Meier analysis. Exact p-values and datasets are located within the Source Data file. Source data are provided as a Source Data file.

Back to article page